SMTL ID : 6c4d.2 (3 other biounits)

Structure based design of RIP1 kinase inhibitors

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.52 Å

Oligo State

monomer

Ligands

1 x EJP: (3S)-3-(2-benzyl-3-chloro-7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-5-methyl-4-oxo-2,3,4,5-tetrahydro-1,5-benzoxazepine-8-carbonitrile(Non-covalent)

EJP.1: 19 residues within 4Å: Chain A: V.34, I.46, M.47, K.48, M.70, V.78, V.79, L.81, L.93, M.95, L.132, H.139, I.157, A.158, D.159, L.160, L.162, S.164, F.165 10 PLIP interactions: 10 interactions with chain A Hydrophobic interactions: A:V.34, A:I.46, A:L.81, A:L.132, A:D.159, A:L.160, A:F.165 Hydrogen bonds: A:D.159 pi-Stacking: A:H.139 Halogen bonds: A:M.70

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Yoshikawa, M. et al., Discovery of 7-Oxo-2,4,5,7-tetrahydro-6 H-pyrazolo[3,4- c]pyridine Derivatives as Potent, Orally Available, and Brain-Penetrating Receptor Interacting Protein 1 (RIP1) Kinase Inhibitors: Analysis of Structure-Kinetic Relationships. J. Med. Chem. (2018)

Release Date

2018-03-21

Peptides

Receptor-interacting serine/threonine-protein kinase 1: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
B

Receptor-interacting serine/threonine-protein kinase 1

Related Entries With Identical Sequence